Fagron N.V. (FAGR.BR) Stock Analysis & Winston Score

Fagron is a Belgian healthcare company that makes custom-made medicines for patients who need something a regular pharmacy cannot provide off the shelf. For example, a doctor might need a specific dose or ingredient combination that no standard drug company makes — Fagron's pharmacists mix and prepare those medicines to order. This practice is called pharmaceutical compounding, and Fagron is one of the largest compounding companies in the world. Fagron earns money by selling compounded medicines and the raw ingredients, equipment, and software that hospital and retail pharmacies need to do their own compounding. It operates across more than 30 countries, with strong positions in Europe, the United States, and Latin America, generating roughly €700–800 million in annual revenue. Its main competitive advantage is its scale and regulatory expertise, since compounding is heavily regulated and hard for smaller players to navigate. The key growth driver is rising demand for personalized medicine, though stricter pharmacy regulations — especially in the US — remain an ongoing risk to its business model.